Marstacimab
Orphan Drug Cold Chain RequiredFDA Approved (2024)
Contents
Description
A tissue factor pathway inhibitor (TFPI) antagonist monoclonal antibody given subcutaneously for hemophilia A or B without inhibitors. FDA-approved October 2024.
Indications & Therapeutic Use
Hemophilia A or B without inhibitors
Linked Diseases:
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| Standard Marketing Authorization | — | — | Approved |
Buy / Source Marstacimab — GNH India
4 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Marstacimab products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Marstacimab
| Generic Name | marstacimab |
| Brands | 1 brand available |
| Active Ingredient | marstacimab |
| Drug Class | Hemophilia A or B without inhibitors |
| Manufacturer | Pfizer |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Reg. Status | FDA Approved (2024) |
| Countries | 1 countries |
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes